1. Home
  2. FMAO vs TENX Comparison

FMAO vs TENX Comparison

Compare FMAO & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmers & Merchants Bancorp Inc.

FMAO

Farmers & Merchants Bancorp Inc.

HOLD

Current Price

$26.90

Market Cap

366.8M

Sector

Finance

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$11.97

Market Cap

308.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMAO
TENX
Founded
1897
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
366.8M
308.0M
IPO Year
1996
2001

Fundamental Metrics

Financial Performance
Metric
FMAO
TENX
Price
$26.90
$11.97
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$28.50
$29.67
AVG Volume (30 Days)
77.1K
636.7K
Earning Date
04-22-2026
05-15-2026
Dividend Yield
3.45%
N/A
EPS Growth
27.89
N/A
EPS
0.70
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.20
N/A
P/E Ratio
$38.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.59
$5.34
52 Week High
$29.83
$18.38

Technical Indicators

Market Signals
Indicator
FMAO
TENX
Relative Strength Index (RSI) 49.58 41.29
Support Level $25.59 $10.83
Resistance Level $27.36 $14.15
Average True Range (ATR) 0.79 0.91
MACD -0.08 -0.12
Stochastic Oscillator 35.87 14.79

Price Performance

Historical Comparison
FMAO
TENX

About FMAO Farmers & Merchants Bancorp Inc.

Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in one segment which is commercial banking. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: